miR-34a also targets SIRT1, which is pharmacologically beneficial for obesity disorders since it has been shown that SIRT1 activity increases oxidative metabolism as well as mitochondrial function (Fig. 1) [93, 95]. Here, SIRT1 is linked to Obesity.